Titan Pharmaceuticals TTNP shares are trading higher on Wednesday after the company announced a deal to buy JT Pharma Kappa Opioid with a gross proceeds of at least $8 million.
Titan Pharmaceuticals is a specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products. The company product pipeline consists of Probuphine for Opioid addiction, Ropinirole for Parkinson's disease, Triiodothyronine (T3) for hypothyroidism. It generates revenue principally from collaborative research and development arrangements, technology licenses, and government grants.
Titan Pharmaceuticals shares traded up 29.88% to 17 cents on Wednesday. The stock has a 52-week high of 54 cents and a 52-week low of 11 cents.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
